GLENMARK LIFE SCIENCES LIMITED IPO
Open for Subscription

India Pesticides Limited IPO
`695 -
`720

Why subscribe to Glenmark Life Sciences Limited?

Glenmark Life Sciences Limited is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (API) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. The company also manufactures and sells APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas. Glenmark Life Sciences is also increasingly providing contract development and manufacturing operations (CDMO) services to a range of multinational and specialty pharmaceutical companies. The company’s API portfolio comprises specialized and profitable products, including niche and technically complex molecules, which reflects its capability to branch into other high value products. The company has a strong market share in select specialized APIs such as Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (antihypertensive), Teneligliptin (diabetes), Zonisamide (CNS) and Adapalene (dermatology).

Objects of the Offer: The offer comprises a fresh issue and an offer for sale. The fresh issue is of ₹1,060cr out of which ₹800cr would be used for the Payment of outstanding purchase consideration to the Promoter for the spin-off of the API business from its Promoter, Glenmark Pharmaceuticals Limited into the company i.e. Glenmark Life Sciences Limited. Further, ₹152.7cr of the fresh issue would be used for funding the capital expenditure requirements and the remaining proceeds from the fresh issue would be used for General corporate purposes. The offer for sale is comprised of ₹453.6cr, the proceeds of which would be given to the selling shareholders and no part of it would be given to the company.

Click here for complete report.

New Customer?
Open IIFL Demat Account



OPEN DEMAT ACCOUNT

If You Are An Existing
Customer

Click To Invest

Subscribe now

Issue Highlights

  • 27-July-21
  • 29-July-21
  • ` 695 - ` 720 per share
  • ` 2 per equity share
  • ` 1,513.6 crores
  • 20 Shares
  • Bombay Stock Exchange
    & National Stock Exchange
  • 50%
  • 15%
  • 35%